APA (7th ed.) Citation

Trovato, E., Cartocci, A., Gaiani, F., Messina, F., Mastorino, L., Macagno, N., . . . Satolli, F. (2026). Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis). Dermatology & Therapy, 16(3), 1675. https://doi.org/10.1007/s13555-026-01662-9

Chicago Style (17th ed.) Citation

Trovato, Emanuele, et al. "Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)." Dermatology & Therapy 16, no. 3 (2026): 1675. https://doi.org/10.1007/s13555-026-01662-9.

MLA (9th ed.) Citation

Trovato, Emanuele, et al. "Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)." Dermatology & Therapy, vol. 16, no. 3, 2026, p. 1675, https://doi.org/10.1007/s13555-026-01662-9.